Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.China Nuokang Bio-Pharmaceutical (Nuokang), a biopharma company focused on the manufacturing, R&D, marketing and sales of hematological and cardiovascular products, has reported net revenues of RMB82.85m for the fourth quarter ended December 31, 2009, an increase of 15.3%, compared to RMB71.88m for the same period in 2008.
Subscribe to our email newsletter
Operating income was RMB26.67m, compared to RMB24.25m for the prior year period.
China Nuokang has posted a net income of RMB23.45m, or RMB0.18 per diluted share, an increase of 7.1%, compared to RMB21.9m, or RMB0.17 per diluted share, for the comparable period in 2008.
For the full year ended December 31, 2009, China Nuokang has posted a net income of RMB65.09m, or RMB0.51 per diluted share, compared to RMB63.62m, or RMB0.43 per diluted share, for the year ago period.
Net revenue was RMB282.91m for the 12 months, an increase of 25.5% compared to RMB225.39m for the year ago period. Operating income was RMB80.89m, compared to RMB64.56m for the year ago period.
Baizhong Xue, chairman and CEO of China Nuokang, said: “We are very pleased with our fourth quarter and full year 2009 financial results, which reflect operational strength across the company, as well as Baquting’s continued market leadership as the number one hemocoagulase brand in China.
“With a successful initial public offering completed and historically strong financial results, this was a landmark fourth quarter for Nuokang and demonstrated our high product quality, efficient operating platform and national presence compared to our competitors.”